# Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

> **NCT00058422** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 65 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** darbepoetin alfa
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **RADIATION:** indium In 111 ibritumomab tiuxetan
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00058422
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02-10
- **Primary completion:** 2019-11-14
- **Final completion:** 2019-11-14
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058422, "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00058422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*